LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

Cara Therapeutics Inc

Затворен

Сектор Здравеопазване

0.29 -6.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.29

Максимум

0.31

Ключови измерители

By Trading Economics

Приходи

-28M

Продажби

-1.9M

3M

EPS

-0.59

Марж на печалбата

-576.079

Служители

55

EBITDA

-29M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+212.5 upside

Дивиденти

By Dow Jones

Следващи печалби

11.11.2024 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-2.3M

46M

Предишно отваряне

6.74

Предишно затваряне

0.29

Настроения в новините

By Acuity

79%

21%

321 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Cara Therapeutics Inc Графика

Свързани новини

6.09.2024 г., 22:41 ч. UTC

Пазарно говорене

KinderCare and StandardAero File for IPOs -- Market Talk

6.09.2024 г., 21:18 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6.09.2024 г., 21:05 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 20:39 ч. UTC

Печалби

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6.09.2024 г., 20:35 ч. UTC

Топ новини

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6.09.2024 г., 20:34 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6.09.2024 г., 20:11 ч. UTC

Топ новини

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6.09.2024 г., 19:51 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6.09.2024 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Gains -- Market Talk

6.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6.09.2024 г., 19:01 ч. UTC

Пазарно говорене

Gold Slips on Prevailing Uncertainty -- Market Talk

6.09.2024 г., 18:27 ч. UTC

Топ новини

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6.09.2024 г., 18:25 ч. UTC

Пазарно говорене

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6.09.2024 г., 18:15 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6.09.2024 г., 18:12 ч. UTC

Топ новини

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6.09.2024 г., 17:44 ч. UTC

Пазарно говорене

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Пазарно говорене

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Топ новини

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6.09.2024 г., 17:27 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in August -- Market Talk

6.09.2024 г., 16:36 ч. UTC

Пазарно говорене

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6.09.2024 г., 16:35 ч. UTC

Печалби
Горещи акции

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6.09.2024 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Печалби

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cara Therapeutics Inc Прогноза

Ценова цел

By TipRanks

212.5% нагоре

12-месечна прогноза

Среден 1 USD  212.5%

Висок 1 USD

Нисък 1 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Cara Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

0

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

0.3145 / 0.36Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

321 / 365 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

$

Относно Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.